Trials / Completed
CompletedNCT05886933
Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet
A Prospective, Non-Intervention, Multi-Center Observational Study to Evaluate the Efficacy and Safety of FEXUCLUE Tablet in Patients With Erosive Gastroesophageal Reflux Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 9,846 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 19 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This observational study is a large-scale, prospective, and multi-institutional observational study. Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.
Detailed description
Data will be collected based on patient's medical records from daily visit. Enrolled subjects will take a Patient Reported Outcome (PRO) survey including Quality of life evaluation (GERD-HRQL) and self-awareness symptom (RDQ). The survey will be done twice (before and after the administration of Fexuclue tablet) electronically through an application (e-PRO).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fexuprazan Hydrochloride | Patient treated with Fexuprazan Hydrochloride (Fexuclue Tablet) |
Timeline
- Start date
- 2023-05-22
- Primary completion
- 2024-04-30
- Completion
- 2024-12-31
- First posted
- 2023-06-02
- Last updated
- 2025-01-24
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05886933. Inclusion in this directory is not an endorsement.